In this study, using HDAC inhibitors that induce selective chromatin remodeling events to alter specific gene expression patterns with accurate dosage settings and specificity will trigger a new wave of drugs with refined strategies for the treatment of human CML or IR CML malignancies. This evidence concerns the gene HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive.